Sigma Ends Boots Bid as $10 Billion Pharmacy Deal Falls Apart
Sigma Healthcare has ended talks to buy Boots, walking away from a deal valued at about $10 billion and leaving the future of the U.K. pharmacy chain uncertain.
Health
Read more
Novartis to Acquire Avidity Biosciences for $12 Billion to Boost Rare-Disease Portfolio
Novartis announced a $12 billion all-cash acquisition of Avidity Biosciences, gaining access to RNA-based therapies for rare muscle disorders. The move aligns with the company’s broader push into gene and precision-medicine platforms as it faces upcoming patent expirations on key blockbuster drugs.